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Abstract.  The binding of neutrophils  (polymor- 
phonuclear leukocytes [PMNs]) to endothelial cells 
(ECs) presents special requirements  in the regulation 
of intercellular adhesion.  ECs that are stimulated by 
certain agonists,  including thrombin and cytokines (tu- 
mor necrosis factor or,  interleukin-1),  generate molecu- 
lar signals that induce the adhesion of PMNs (en- 
dothelial cell-dependent neutrophil adhesion).  Our 
experiments demonstrate that the mechanism of bind- 
ing induced by thrombin  is distinct from that induced 
by the cytokines based on the time courses, the re- 
quirement for protein synthesis,  and differential bind- 
ing of HL60 promyelocytic leukemia cells to ECs acti- 
vated by the two classes of agonists.  The rapid 
EC-dependent PMN adhesion (initiated  in minutes) 
that occurs when the ECs are stimulated by thrombin 
is temporally coupled with the accumulation of 
platelet-activating  factor, a biologically active phos- 
phoglyceride that remains associated with ECs and 
that activates PMNs by binding  to a cell surface recep- 
tor.  A portion of the newly synthesized platelet- 
activating factor (PAF) is on the EC  surface, as 
demonstrated by experiments in which the rate of hy- 
drolysis of PAF synthesized by activated ECs was ac- 
celerated by extracellular  PAF acetylhydrolase. When 
ECs were treated with exogenous PAF they became 
adhesive for PMNs; the PMN binding was prevented 
by incubating the ECs with PAF acetylhydrolase or by 
treating  the PMNs with competitive PAF receptor an- 
tagonists.  Thus PAF associated with the EC plasma 
membrane induces PMN binding,  an observation sup- 
ported by experiments in which PAF in model mem- 
branes (liposomes) stimulated rapid PMN adhesion to 
ECs and to cell-free surfaces.  In addition,  competitive 
antagonists of the PAF receptor inhibited the binding 
of PMNs to ECs activated by thrombin and other rap- 
idly acting agonists,  but not to ECs activated by tumor 
necrosis factor c~, indicating  that PAF that is en- 
dogenously synthesized by ECs can mediate neutrophil 
adhesion.  These experiments demonstrate a novel 
mechanism by which a cell-associated phospholipid, 
PAF, can serve as a  signal for an intercellular  adhesive 
event. 
T 
HE interaction  of circulating  blood cells with the en- 
dothelial  cells (ECs) ~ that  line  vessels presents  spe- 
cial requirements  in the signaling and regulation of in- 
tercellular  adhesion,  a fundamental biologic process. Under 
usual  physiologic  conditions  blood cells  remain  separate 
from ECs or loosely associated with them, as in the case 
of the  "marginal  pool" of polymorphonuclear  leukocytes 
(Athens  et al.,  1961). However, under other conditions  in- 
dividual types of blood cells adhere to localized areas of the 
vessel wall,  in response to specific stimuli,  to perform ho- 
meostatic  functions.  Examples  include  the accumulation  of 
platelets  at injured  areas of vessels,  which is required for 
hemostasis,  and the adhesion of leukocytes to ECs as the first 
step in their migration  to sites of extravascular  infection or 
1. Abbreviations  used in this paper:  AH, acetylhydrolase;  EC, endothelial 
cell; ELAM, endothelial cell leukocyte adhesion molecule; fMLP, n-formyl- 
methionyl-leucyl-phenylalanine; HBSS/A, I-IBSS  with 0.5 % human albumin; 
IL, interleukin I; LDL, low density lipoprotein;  PAF, platelet-activating fac- 
tor; PMN, polymorphonuclear leukocyte;  TNF,  tumor necrosis factor. 
injury,  a process that  is required for host defense.  Under 
physiologic conditions avid binding of myeloid leukocytes to 
ECs, which occurs in segments  of the vasculature  adjacent 
to sites harboring  inflammatory  stimuli,  is reversible (allow- 
ing leukocytes to migrate to extravascular sites), and involves 
differential  signaling  for different  kinds of leukocytes.  For 
example,  polymorphonuclear  leukocytes  (PMNs;  neutro- 
phils)  accumulate rapidly  at  sites  of acute inflammation, 
whereas the accumulation of  mononuclear leukocytes occurs 
later and is more prolonged (van Furth et al.,  1979). 
Two general  mechanisms  for adhesion  of PMNs to EC 
have  been  identified.  The  first  involves  activation  of the 
PMNs  by chemotactic  factors  (n-formylmethionyl-leucyl- 
phenylalanine [fMLP],  leukom'ene 134, C5a) and agents such 
as PMA, resulting  in altered expression  of surface adhesive 
proteins  (CD,/CD~s heterodimers)  (Anderson et al.,  1986) 
that are members of the integrin  superfamily  (Kishimoto  et 
al.,  1987). At least one of these, CD,b/CD~s, interacts with 
molecular targets on ECs (Wallis et al.,  1986; Zimmerman 
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adhesion molecule 1 (ICAM-1) on ECs appears to be a ligand 
for  CD,/CD~s  molecules on  stimulated PMNs  (Smith  et 
al.,  1988).  The CD,/CD,s-dependent mechanism of adhe- 
sion is nonspecific, since it mediates aggregation of PMNs 
and their adhesion to matrix proteins and to a variety of  other 
cells in addition to endothelial cells (Anderson et al., 1986; 
Wallis et al.,  1986;  Simon et al.,  1986;  Zimmerman and 
Mclntyre, 1988; Wright et al.,  1988). 
In the second general mechanism ECs, rather than PMNs, 
are first activated, causing them to express molecules that 
promote  PMN  binding  (EC-dependent  PMN  adhesion) 
(Zimmerman et al., 1985, 1986). EC-dependent PMN adhe- 
sion may be the relevant mechanism for the physiological in- 
teraction of  neutrophils with ECs since it would target PMNs 
to specific areas of the intimal surface. There are at least two 
forms of EC-dependent adhesion of neutrophils. One occurs 
within minutes after exposure to thrombin and certain other 
agonists (Zimmerman et al.,  1985;  Mclntyre et al.,  1986; 
Lewis et al.,  1988).  The other appears over hours in re- 
sponse to the cytokines interleukin-1  (IL-1), tumor necrosis 
factor (TNFa),  and lymphotoxin (TNF/3),  or to endotoxin 
(Bevilacqua et al., 1985; Gamble et al., 1985; Schleimer and 
Rutledge, 1986; Broudy et al.,  1987).  The cytokine-stimu- 
lated response is temporally associated with the expression 
of a newly synthesized glycoprotein, termed endothelial cell 
leukocyte adhesion moleculeq (ELAM-1), that mediates PMN 
adhesion and also promotes the binding of other myeloid 
cells (Bevilacqua et al., 1985, 1987, 1989). In contrast, EC- 
dependent PMN adhesion induced by thrombin and other 
rapidly acting agonists is temporally coupled with the syn- 
thesis of platelet-activating factor (PAF;  1-O-alkyl-2-acetyl- 
sn-glycero-3-phosphocholine) (Prescott et al.,  1984;  Zim- 
merman et al.,  1985;  Mclntyre et al.,  1986;  Lewis et al., 
1988), a unique glycerophospholipid that activates PMNs, as 
well as platelets and other cells, by interacting with cell sur- 
face receptors (Hanahan,  1986;  Hwang, 1988). 
Earlier, we proposed that the PAF that is synthesized by 
activated EC is a signal for PMNs to bind (Prescott et al., 
1984; Zinunerman et al., 1985). This conclusion was based 
on several  lines of evidence, of which the most compelling 
was the demonstration that selective desensitization of the 
PAF receptor on PMNs blocked their adhesion to thrombin- 
or LTC4-stimulated  ECs (Zimmerman et al.,  1985;  Mcln- 
tyre et al., 1986).  However, the precise role of PAF was un- 
certain since we found that newly synthesized PAF remained 
associated with ECs, rather than being released into the fluid 
phase (Prescott et al.,  1984;  Mclntyre et al.,  1985),  and it 
was unknown if it could function as a mediator of intercellu- 
lar interaction when presented in association with a mem- 
brane surface (Zimmerman et al., 1985).  Furthermore, the 
desensitization studies could have been flawed if there were 
effects other than "homologous desensitization" of the PAF 
receptor that were not manifest in our controls for selectivity 
(Sibley et al.,  1987).  In this report  we present evidence 
demonstrating that EC-derived PAF mediates PMN binding 
to thrombin-stimulated endothelium. We also further differ- 
entiate the mechanism of binding stimulated by rapidly act- 
ing agonists and that stimulated by cytokines. These experi- 
ments demonstrate a novel mechanism for cell-cell interac- 
tion, in which a cell-associated lipid mediator, PAF, acts to 
induce rapid and reversible intercellular adhesion, a process 
usually ascribed to glycoproteins or lectins (Ekblom et al., 
1986;  Edelman,  1986;  McC ay and Ettensohn, 1987). 
Materials and Methods 
Materials 
PAF was purchased from Avanti  Polar  Lipids,  Inc.  (Birmingham,  Ala- 
bama), and [sn-2-3H-acetyl]PAE [I-O-3H-alkyl]PAE and [3Hlacetate  were 
from New England Nuclear (Boston, MA). Purified human thrombin was 
a gift from John Fenton (Albany, NY).  Recombinant human TNF¢ (5  x 
107 U/mg; lot 3056-63)  was provided by John Kaumeyer of Genentech, 
Inc. (San Francisco, CA) and recombinant human IL-I, (2.1  x  107 U/rag; 
lot SM-47) was provided by Peter Lomedico (Department of Molecular 
Genetics, Hoffman-La Roche Inc., Nutley,  N  J).  Leukotrienes B4 and C4 
were gifts from Joshua Rokach,  Merck-Frosst Laboratories (Montreal, 
Canada).  Phospholipase A2  from bee venom was from Sigma Chemical 
Co., (St. Louis, MO). H  qedium oxine was purchased from the Radiophar- 
macy Service at the University of Utah, and human serum albumin (25% 
USP) from Miles Laboratories Inc. (Elkhart, IN). Medium 199, RPMI 1640, 
and Hanks' balanced salt solution (HBSS) were from Whittaker M. A. Bio- 
products (Walkersville,  MD),  and FBS was from HyCIone Laboratories 
(Logan, UT). 
Endothelial Cells 
Monolayers of  human umbilical vein ECs were cultured in multiwell plates 
(16-ram wells; Costar Data Packaging Corp., Cambridge, MA) or individual 
35-ram dishes as described (Zimmerman et al.,  1985,  1989).  Only tightly 
confluent, primary EC monolayers were used for these experiments. 
Measurement of Neutrophil Binding to ECs and to 
Protein Matrices 
Human neutrophils were isolated from beparinized or EDTA-treated  blood 
and were labeled with mIndium as described (Zimmern~n et al.,  1985). 
The binding assays have been reported previously  (Zimmerman et al., 
1985). Briefly, EC monolayers were washed with HBSS and incubated with 
control buffer or an agonist in HBSS with 0.5% human albumin (HBSS/A) 
for variable time periods. The incubation mixture was then removed, the 
monolayers were  rapidly  washed  with  HBSS,  and  llqn-labeled PMNs 
were added and incubated for 5 min. Nonadherent PMNs were removed, 
the monolayers were washed with HBSS, the adherent radiolabeled PMNs 
and the ECs were solubilized, and the fraction of adherent PMNs (percent- 
age of total radiolabeled PMNs added) was quantitated. In incubations with 
TNF-t~ or IL-1, the cytakine or control buffer was added to complete culture 
medium for various time periods (usually 4 h). The medium was then re- 
moved, the ECs were washed, and t NIn-labeled PMN adhesion was deter- 
mined after a 5-min incubation. In some experiments ECs were washed, 
t l iin_labele  d  PMNs were added followed by addition of control buffer or 
an agonist, and PMN binding was measured after a  variable incubation 
time, usually 5 min. 
i l qn-labeled PMN binding to protein matrices, made by treating culture 
wells with gelatin (2,000 #g/ml; type A, Fisher Scientific Co, Fair Lawn, 
NJ) for 1 h at 37°C, was measured as described (Zimmerman and McIntyre, 
1988;  Lewis et al.,  1988).  Briefly,  the matrices were washed once with 
HBSS (37°C),  Hqn-labeled PMNs were layered over them, PAF or an- 
other agonist was added, and adhesion was measured after a 5- or 15-min 
incubation period. 
In experiments with fixed EC monolayers, the ECs were incubated with 
control buffer or an agonist, the solutions were removed, and then a fixative 
solution was added. These included glutaraldehyde (2.5 %), paraformalde- 
hyde (2%), or 1CA (5%). The monolayers were incubated a minimum of 
10 min at room temperature, washed three times with buffer, and incubated 
with ~HIn-labeled  PMNs for 5 rain. The fraction of adherent PMNs was 
determined as with unfixed ECs. 
Stimulation of  PMN  Binding with Liposomal PAF 
Preparation  of  control  and  PAF-loaded  liposomes  was  done  using  a 
modification of the method described by Lumb et al., (1983).  Briefly,  20 
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evaporated to dryness under nitrogen in a clean glass tube. 2 ml of I-IBSS 
was added,  the lecithin was resuspended using a  vortex device, and the 
resultant suspension  was sonicated at 100 W for 30 rain in a sonicator (1510; 
B. Braun Instruments, Burlingume, CA) and was then centrifuged for 30 min 
at 21,500 g (13,500 rpm) at 4"C in a centrifuge with a J21 rotor (Beckman 
Instruments, Inc., Palo Alto, CA). The liposome-rich supernatant was col- 
lected and a portion was used for loading with PAE PAF in various amounts 
in chloroform was evaporated to dryness under nitrogen. 1 ml of liposome 
suspension was added and the suspension was vigorously mixed by vortex- 
ing. In parallel, radiolabeled PAF mixed with unlabeled PAF was dried and 
mixed with liposomes. The liposomal suspensions were loaded onto Sepha- 
rose 613 columns and eluted at 15 drops per tube with HBSS. The fractions 
containing liposomes, monitored by elution of  liposomes loaded with radio- 
labeled PAE were collected. The concentration of  PAF in the liposomes was 
calculated based on the recovered labeled PAF and its specific activity, and 
the suspensions  were diluted to the desired concentrations with HBSS. Con- 
trol or PAF-loaded liposomes were added to rain-labeled PMN suspensions 
and the adhesion of the PMNs to ECs or protein matrices was measured 
as described previously. 
Measurement of  ilL60 Cell Binding to ECs 
HL60 promyelocytic leukemia cells were the gift of Jerry Kaplan, Univer- 
sity of Utah, or were obtained from the American Type Culture Collection 
(Rockville, MD), and were maintained in tissue culture flasks in medium 
RPMI 1640 supplemented with 20% heat-inactivated FBS. The cells were 
passed (usually every 3 d) when they reached a concentration of 106/ml by 
diluting them to a  concentration of 2  ×  105 cellslml. Their adhesion to 
ECs or to protein matrices was usually studied after 15-20 passages because 
basal adhesion was variable at earlier stages. For adhesion studies, HL60 
cells were counted, centrifuged at 1350 rpm for 5 rain at 20°C, and washed 
by resuspending them in 10 ml I-IBSS/A. They were again centrifuged as 
described, resuspended in 5 ml HBSS/A, and incubated with t l qndium ox- 
ine (0.5/~Ci/106)  cells at 3"/°C for 20 min. The mln-labeled cells were 
centrifuged (1350 rpm, 5 rain, 200C), washed in 10 ml HBSS/A, and again 
pelleted using  the same centrifugation conditions. The cells were then 
resuspended in an appropriate volume of  HBSS/A to yield a final concentra- 
tion of 5.5  ×  106 cells/ml. The binding assay was done as described for 
i i qn-labeled PMNs.  The adhesion of HL60  cells used in these experi- 
ments to ECs or gelatin matrices was not increased over control when the 
cells were incubated with PAF (10-9-10 -6 M),  fMLP (10-9-10 .-6 M),  or 
PMA (10 or 100 ng/ml) for 5 or 30 min, indicating that they did not become 
adhesive in response to these agents. 
Measurement of  pH-Acetyl]PAF  Accumulation in 
Stimulated ECs 
PAF accumulation was measured by the incorporation of [3H]acetate  into 
[3H-acetyl]PAF as described in detail elsewhere (Mclntyre et al.,  1985; 
Whatley et al.,  1988). 
Degradation of  pH-Acetyl]PAF  Associated with ECs by 
Exogenous Phospholipases 
Medium was removed from EC monolayers, they were washed with HBSS, 
and  incubated with [3H]acetate and thrombin or another agonist as de- 
scribed in (McIntyre et al.,  1985)  and Fig. 3. After an incubation period 
that was chosen to induce maximal accumulation of [3H-acetyl]PAF based 
on previous studies (Prescott et al.,  1984;  McIntyre et al.,  1986)  (when 
thrombin was the agonist, this was 10 rain), the monolayers were rapidly 
washed and incubated for various times at room temperature or 37"C with 
control buffer or PAF acctylhydmlase  (AH) pru'Vmations. The [3H-acctyl]PAF 
that remained after incubation of the ECs under these conditions was ex- 
tracted and quantitated as described (McIntyre et al., 1985). In some experi- 
ments ECs were stimulated to synthesize [3H-acetyl]PAF,  washed, fixed 
with glutaraldehyde or TCA and incubated with PAF AH or phospholipase 
A2.  PAF AH in low density lipoprotein (LDL) particles was prepared as 
described (Statforinl et al., 1987a,b). In some experiments  the AH was inac- 
tivated by treatment with diisopropylfluoro-phosphate (DFP) as described; 
DFP was removed by dialysis before use of  the LDL-AH preparations (Staf- 
forinl et al.,  1989).  Activity of the AH preparations was confirmed using 
our previously described assay (Stafforini et al.,  1987a,b). 
Experiments with Competitive PAF Receptor 
Antagonists 
L652,731,  L659,989,  and kadsurenone were generously supplied by John C. 
Chabala, Ph. D of Merck, Sharp, and Dohme Research Laboratories (Rah- 
way, N  J). The powdered reagent was not directly soluble in aqueous buffer and 
therefore 100-raM stock solutions were made in 100% DMSO and used im- 
mediately or frozen at -20°C until use. The inhibitor solution was then sub- 
diluted to a concentration of I mM by slowly adding 25 #1 of the 100-raM 
stock solution to 2.475 ml of HBSS that had been prewarmed to 37°C. It 
was essential to prewarm the buffer and to keep the subdiluted solution at 
37°C during the experiment to prevent precipitation of  the L652,731.  In sev- 
eral experiments precipitates of L652,731  formed in the subdiluted solution 
even when kept at 37°C,  requiring preparation of a new solution.  1 vol of 
the l-raM solution was added to 9 vol of mln-labeled PMNs (room tem- 
perature) to yield a  final concentration of 100  #M  L652,731  and 0.1% 
DMSO, and the PMNs were incubated for 5 min at room temperature before 
addition to ECs or protein matrices. Aliquots of  the l-raM inhibitor solution 
were further diluted with prewarmed HBSS before adding to PMNs when 
lower concentrations  of  inhibitor were used. Control neutrophil suspensions 
were treated in side-by-side  fashion with DMSO that was diluted in an iden- 
tical way to the inhibitor solutions, yielding a final concentration of DMSO 
that was the same in both control and L652,731-treated  PMN suspensions. 
L652,989 and kadsurenone solutions were prepared in the same way as with 
L652,731  and DMSO control solutions were used in parallel with these in- 
hibitors as well. In each experiment, we documented inhibition of PMN 
binding induced by exogenous PAF by the competitive receptor antagonists 
as a positive control. 
Results 
EC-dependent PMN Adhesion Induced by 
Thrombin and by Cytokines Involve Different 
Molecular Mechanisms 
Thrombin  induces a  2-10-fold increase  in the binding of 
PMNs to ECs. The enhanced adhesion occurs when throm- 
bin is added to PMNs suspended in buffer (Fig. 1 A) or serum 
(not shown) overlying EC monolayers, as well as when ECs 
are pretreated with thrombin before addition of the PMN 
suspension (Fig.  1 B). The response has a similar time de- 
pendency under both conditions (Zimmerman et al.,  1985, 
1986).  We found in direct side-by-side experiments that the 
time courses of EC-dependent PMN adhesion induced by 
thrombin and by TNFcx are dramatically different. The throm- 
bin-stimulated response is measurable within minutes, peaks 
at 5-10 min, and decays over the next 30-50 min (Fig.  1), 
whereas TNF-induced EC-dependent adhesion of PMN re- 
quires 30-60 min before enhanced PMN binding occurs, is 
maximal at ,,~240 min, and is sustained over several hours 
(Fig. 1; Gamble et al., 1985).  The rapid onset of neutrophil 
binding induced by thrombin is similar to that induced by 
leukotrienes C, and D, and hydrogen peroxide (McIntyre et 
al.,  1986;  Lewis et al.,  1988),  and by histamine (Zimmer- 
man, G. A., manuscript in preparation). Thus, the kinetics of 
binding,  together with the transient duration, differentiate 
the effect of thrombin and other rapidly acting agonists from 
the TNFc~ effect. The TNFcx time dependency is similar to 
that induced by IL-1 and by lipopolysaccharide (Bevilacqua 
et al., 1985; Schleimer and Rutledge, 1986). A second differ- 
ence is the requirement for protein synthesis for the EC to 
become proadhesive. EC-dependent leukocyte binding stim- 
ulated by TNFcx and other cytokines requires protein synthe- 
sis and is inhibited by cycloheximide  or actinomycin D (Gam- 
ble et al.,  1985;  Bevilacqua et al.,  1985).  We found (two 
experiments) that the thrombin-induced effect was not blocked 
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Figure I.  (A) Rapid and slow 
endothelial  cell-dependent 
PMN  adhesion  induced  by 
thrombin  and  TNFtx.  EC 
monolayers  were  pretreated 
with  recombinant  TNFot for 
the  indicated  times,  washed, 
and  rain-labeled  PMNs were 
added;  adhesion  of  labeled 
PMNs was determined after a 
5-min period. In parallel incu- 
bations  "qn-labeled  PMNs 
were  added  to  washed  EC 
monolayers,  thrombin  (2  U/ 
ml, 18.5 nM) was added, and 
adhesion  of  labeled  PMNs 
was determined  at the  times 
indicated. The latter protocol was chosen to demonstrate the rapidity with which thrombin induces EC-dependent PMN adhesion. We previ- 
ously showed that pretreatment of EC monolayers with thrombin for various times, followed by washing and incubation with "qn-labeled 
PMNs, caused EC-dependent adhesion with the same time course as that illustrated (Zimmerman et al.,  1985) (see also Fig.  1 B). (B) 
Thrombin induces EC-dependent binding of PMNs but not HL60 promyelocytic leukemia cells. EC monolayers were pretreated with buffer 
or thrombin (2 U/ml) in HBSS/A for 10 min and washed, rain-labeled PMNs or HL60 cells were added, and the adherence of the leuko- 
cytes was determined after a 5-min incubation. Additional monolayers were treated with IL-lc~ for 4 h in complete medium and washed, 
and the adhesion of |"In-labeled HL60 cells was determined after a 5-min incubation.  Each bar represents the mean results from three 
experiments except for IL-  1  ot (two determinations). The standard deviations for each bar were, for PMNs, 2 % (buffer), and 13 % (thrombin); 
for HL60 cells,  6% (buffer), 4% (thrombin),  and 8% (IL-lo0. 
by pretreatment of the ECs with cycloheximide (10 #g/ml for 
4 h) before thrombin stimulation. In contrast, the same con- 
centration of cycloheximide inhibited EC-dependent binding 
in  response  to  various  concentrations  of TNFc~  (4  h)  by 
75-85 %. A third feature differentiates the rapid and slow EC 
responses.  HL60 promyelocytic leukemia cells,  as well as 
PMNs,  adhere  to  cytokine-treated  EC  (Bevilacqua et al., 
1985,  1987,  1989). We compared the binding of these cells 
and PMNs to EC activated with TNF or thrombin. There was 
no  increase  in  binding  of HL60 cells to thrombin-treated 
ECs  compared  with  control  EC  monolayers  (Fig.  1  B), 
whereas there was a 3-10 fold increase in adherence of HL60 
cells to ECs treated with TNFot or IL-1 (Table I). Thus, the 
rapid, thrombin-induced PMN binding occurs by a mecha- 
nism that is fundamentally different from that induced  by 
cytokines. The experiments with HL60 cells exclude the pos- 
sibility that the thrombin-dependent adhesion involves rapid 
expression of preformed ELAM-1, consistent with the obser- 
vation by Bevilacqua et al. (1987,  1989) that neither ELAM-1 
nor messenger RNA for the protein is present in unstimu- 
lated ECs. The inability of HL60 cells to bind to thrombin- 
activated ECs is consistent with their lack of a  functional 
receptor for PAF (Valone,  1988)  (see below). 
The Proadhesive Activity on Thrombin-stimulated ECs 
Has Characteristics of a Phospholipid 
Experiments to define the chemical nature of the proadhesive 
activity were hampered by the  transient  nature  of the  re- 
sponse in thrombin-treated ECs. However, we found that the 
adhesive surface of the ECs was preserved if the monolayers 
were stimulated with thrombin and then fixed before incuba- 
tion with radiolabeled PMNs (Fig. 2). In contrast, there was 
no enhanced PMN binding if the EC monolayers were fixed 
before treatment  with  thrombin,  demonstrating that  a  re- 
sponse  of the  ECs  was  required.  Washing  of thrombin- 
treated, fixed EC monolayers with albumin-containing buffer 
did not remove the adhesive activity (Fig. 2). However, treat- 
ment of the monolayers with methanol caused loss of the ac- 
tivity (Fig. 2), which suggested that it was a lipid.  We next 
treated  thrombin-stimulated,  fixed  monolayers with  phos- 
pholipase Az and found that it abolished the adhesive activ- 
ity, indicating the involvement of a phospholipid (Fig. 2). In 
contrast, the adhesive activity remained after treatment of the 
monolayers with a variety of proteases (papaln, proteinase K, 
thermolysin; not shown). These results were compatible with 
our hypothesis that PAF is the EC-derived signal for PMNs 
Table I.  Binding of HL60 Promyelocytic  Leukemia  Cells 
to Human Endothelial  Cells 
ECs pretreated  with  HL60 binding  n 
Buffer, 10 min  7 +  4%  9 
Thrombin (2 U/ml),  10 min  6 +  3%  9 
(5 U/ml), 10 min  6 +  2%  3 
PAF (10  -6 M),  I0 min  10 4- 5%  5 
Buffer, 240 min  10 4- 6%  7 
IL-lct (25 U/rnl), 240 min  37 +  13%  7 
TNFta (100 U/ml), 240 min  34 4-  11%  4 
Primary  monolayers of confluent human ECs were washed and preincubated 
with buffer, thrombin,  or PAF for 10 rain (5% CO2,370C).  The incubation 
buffer was removed, the monolayers were washed with HBSS/A, "qn-labeled 
HL60 ceils were added and incubated for 5 rain, and the percentage of leuko- 
cytes  that  adhered  to  the  monolayer  was then  determined  (Materials  and 
Methods). In one experiment there was no difference in the binding of HI.,60 
cells to buffer- or thrombin-trcated  ECs when the leukocytes were incubated 
with the EC monolayers for 30 rain rather than 5 rain. 
In additional incubations buffer, recombinant IL-let, or recombinant TNFa 
was added to ECs in complete culture medium and the monolayers were in- 
cubated for 4 h. They were then washed,  mIn-HL60 cells were added,  and 
binding was determined after a 5-rain incubation period. 
In several experiments,  rain-labeled PMN binding was measured in paral- 
lel with HL60 adhesion; treatment of the monolayers with thrombin (10 min), 
PAF (5 or 10 min), TNFc~ (4 h), or IL-I (4 h) induced PMN binding as expect- 
ed (see text and Fig.  1 B). 
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activated  EC  is degraded  by phospholipase  A2.  EC monolayers 
were incubated with control buffer or thrombin (2 U/ml) for 10 min 
and then fixed by treatment with  1.5% glutaraldehyde for 90 min 
at room temperature. Replicate monolayers were treated identically 
but  were  not  fixed.  Fixed and unfixed monolayers were  rapidly 
washed three  times  with albumin-containing  buffer,  "qn-labeled 
PMNs were added, and PMN binding was measured after a 5-min 
incubation. Additional control or thrombin-stimulated monolayers 
were fixed and incubated with methanol or with phospholipase A2 
(16 U/ml) for 15 min at room temperature,  followed by washing 
with buffer and measurement of radiolabeled PMN binding after a 
5-min incubation.  Phase-contrast  microscopy  demonstrated  that 
the monolayers remained  intact after fixation and after treatment 
with  methanol  or  phospholipase  A2.  In  a  second  experiment, 
phospholipase  A2 treatment  of TNFct-stimulated,  fixed ECs did 
not reduce PMN binding. 
to bind to thrombin-stimulated ECs.  An additional  feature 
suggesting this is that pretreatment of ECs with nonspecific 
inhibitors  of phospholipase  A2  such  as p-bromophenacyl 
bromide (Lewis et al.,  1988), mepacrine, or trifluoperizine 
(our  unpublished  observations)  inhibited  thrombin-stimu- 
lated  PAF  synthesis  and  also  inhibited  thrombin-induced, 
EC-dependent PMN adhesion (Lewis et al., 1988). Thus in- 
hibition  of the  first  step  of the  deacylation-reacetylation 
mechanism for PAF synthesis (remodeling pathway) (Snyder, 
1987),  PLA2-catalyzed hydrolysis of 1-0-alkyl-2-acyl-sn-gly- 
cero-3-phosphocholine yielding  1-0-alkyl-sn-glycero-3-phos- 
phocholine ("lyso-PAF'), the immediate precursor of PAF, 
also inhibited rapid EC-dependent PMN adhesion. However, 
we showed previously that the newly synthesized PAF re- 
mains associated with stimulated ECs and is not released into 
the fluid phase (Prescott et al., 1984; Mclntyre et al., 1985). 
Thus, for endogenously synthesized PAF to interact with its 
receptor on the PMNs, some or all of it would have to be on 
the surface of the EC. 
Newly Synthesized PAF is on the Surface of ECs 
To determine if newly synthesized PAF was on the cell sur- 
face,  we  induced  the  synthesis  of [3H-acetyl]PAF  by  in- 
cubating the ECs with [3H]acetate and thrombin or another 
agonist (pulse).  After an incubation time chosen to induce 
maximal  [3H-acetyl]PAF  synthesis  (Prescott  et  al.,  1984; 
McIntyre  et  al.,  1986),  we  changed  to  buffer  without 
[3H]acetate or  thrombin  and  which  contained  an  enzyme 
that degrades PAF (chase). At subsequent times the loss of 
[3H-acetyl]PAF was measured.  The enzyme used  in these 
experiments was the specific PAF AH from human plasma 
(EC 3.1.1.47) (Stafforini et al., 1987a,b, 1989). This strategy 
was the same as that used by others to determine the "sided- 
ness" of phospholipids in a membrane: the phospholipase is 
not internalized, and, therefore, degradation of a given phos- 
pholipid indicates that it is on the outside of the membrane 
(for review see Op den Kamp, 1979). In our approach, this 
assay was even more specific since the  PAF AH is highly 
selective for short acyl chains at the sn-2 position (Stafforini 
et al., 1987b). Thus, since it will not degrade the usual mem- 
brane phospholipids with long acyl chains at sn-2, its actions 
are unlikely to be due to permeabilization or disruption of 
the plasma membrane. 
Fig.  3  demonstrates that  exogenous AH accelerates the 
degradation of EC-associated PAE In contrast, AH in which 
the catalytic activity had been abolished with DFP (Stafforini 
et al., 1989) did not accelerate the rate of loss. In this experi- 
ment we used isolated LDL particles as a source of partially 
purified AH (LDL-AH) (Stafforini et al., 1987a,b), because 
the lipoprotein environment of the AH affects its catalytic ac- 
tivity and the most favorable environment is in the LDL par- 
ticle (Stafforini et al.,  1989).  However, we also found that 
purified AH (43,500  mol wt)  accelerated the  degradation 
(not shown). The possibility that the LDL-AH was internal- 
ized by the ECs, and acted on PAF located at intracellular 
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Figure 3.  EC-associated  PAF is  accessible  to extracellular  PAF 
acetylhydrolase. ECs were stimulated with thrombin (2 U/ml) in the 
presence  of [3H]acetate for 10 min at room temperature  (pulse) 
and then washed with buffer. A chase was then performed by in- 
cubating the ECs at room temperature with buffer alone, buffer con- 
raining LDL as a source of plasma AH (+LDL), or LDL that had 
been treated with diisopropylfluorophosphate  (DFP) to inactivate 
the AH activity. Isolation  of LDL-AH and its inactivation with 
DFP were done as described (Stafforini et al., 1989). The concen- 
tration of LDL was 0.5 U/ml, which is equivalent to 20% of the 
mean amount in normal  plasma (Stafforini et al.,  1989). At the 
times shown the reaction was stopped by treating the monolayers 
with  acidified  methanol  and  the  content  of [3H-acetyl]PAF was 
measured  (McIntyre  et al.,  1985) as an indicator  of the rate of 
degradation. Each point indicates the mean and standard deviation 
of triplicate determinations.  7,750 +  1,625 cpm and 9,063 +  313 
cpm  of  [3H-acetyl]PAF were  associated  with  monolayers  in- 
cubated with DFP-treated LDL at 15 and  17.5 min, respectively. 
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Figure 4. Competitive PAF receptor antagonists inhibit PAF-stimulated neutrophil binding to protein matrices and to EC. (A) PMNs were 
pretreated with various concentrations of L652,731 or control buffer containing equal concentrations of DMSO for 5 min (see Materials 
and Methods) and were then layered over gelatin matrices. Buffer, PAF (10  -7 M), or fMLP (10  -7 M) was added, and PMN binding was 
assayed after a 15-min incubation. The dashed line indicates the binding of unstimulated PMNs. (o) DMSO-treated PMNs, PAF; (o) 
L652,731-treated PMNs,  PAF; (zx) DMSO-treated PMNs,  fMLP;  (A) L652,731-treated PMNs,  fMLP. (B) rain-labeled  PMNs were 
pretreated with control buffer, L652,731, or kadsurenone, added to EC monolayers, and their adhesion was determined after a 5-rain incuba- 
tion in the presence of various concentrations of PAE In parallel incubations the adhesion of control PMNs and L652,731-treated  PMNs 
in response to fMLP (10  -7 M) was 30 and 25 %, respectively. 
sites, is unlikely since the effect of the LDL-AH was rapid 
and LDL particles are slowly internalized by confluent hu- 
man  ECs  (our  unpublished  observation;  Cotzee  et  al., 
1979). Furthermore, in six experiments AH in LDL parti- 
cles  degraded  PH-acetyl]PAF associated  with  fixed ECs, 
excluding the possibility that internalization of the AH was 
required for hydrolysis of the metabolically labeled PAE In 
these experiments ECs were stimulated to synthesize pH- 
acetyl]PAF with thrombin or calcium Ionophore A23187 as 
in Fig. 3, fixed, and incubated with LDL-AH, DFP-treated 
LDL-AH, or control buffer. In each experiment the LDL- 
AH caused degradation of pH-acetyl]PAF (82-95 % depend- 
ing on the time, the concentrations of LDL, and the fixation 
conditions), whereas the control solutions did not cause hy- 
drolysis. In one of these, the binding of "qn-labeled PMN 
was measured in parallel. The binding of PMNs to thrombin- 
stimulated,  fixed ECs  that  had  been  treated  with  buffer, 
LDL-AH, or DFP-treated LDL-AH was 31, 8.5, and 25%, 
respectively, compared with 9.5 % adhesion to unstimulated, 
fixed EC treated with LDL-AH. There was 94% hydrolysis 
of [3H-acetyl]PAF by LDL-AH in the parallel incubations 
(5,771 cpm in thrombin-activated ECs treated with buffer vs. 
321 cpm in thrombin-stimulated ECs treated with LDL-AI-I). 
From these experiments we conclude that a  substantial 
portion of the PAF synthesized by ECs is on the surface of 
the cell, as indicated by its accessibility to exogenous AH. 
Thus the location of PAF is compatible with the hypothesis 
that it serves as a signal for PMNs to adhere. 
Competitive Antagonists of the PAF  Receptor Inhibit 
EC-dependent NeutrophU Adhesion Induced by 
Thrombin 
As an additional test of this hypothesis, we blocked the re- 
sponses of PMNs to PAF with competitive antagonists of the 
PAF receptor. Kadsurenone, L652,731, and L659,989 spe- 
cifically compete with PAF for binding to cellular receptors 
and block PAF-induced activation of  platelets and leukocytes 
(Shen et al., 1985; Hwang et al., 1985; Hwang et al., 1986; 
Ponpipom et al.,  1988).  We rigorously characterized the 
effects of these antagonists on PAF-induced adhesive responses 
of  neutrophils. In the first series of  experiments we examined 
their inhibition of PAF-stimulated adhesiveness in the absence 
of ECs. L652,731 inhibited PMN aggregation and PMN ad- 
hesion to gelatin matrices in a concentration-dependent fash- 
ion with a maximal effect at 50-100/~M (Fig. 4). The ICs0 
was ~4/~M when 10  -s M PAF was used to stimulate PMN 
binding to gelatin matrices, and  15/~M when 10  -7 M  PAF 
was  used.  The  inhibition  was  specific  for  PAF  because 
L652,731, in the same concentrations, had little or no effect 
(30% inhibition or less) on PMN adhesion induced by fMLP 
(Fig. 4), leukotriene B4, or PMA (not shown). Kadsurenone 
caused a similar concentration-dependent and -specific inhi- 
bition; its potency was equal to, or less than, that of  L652,731 
at equivalent concentrations, as previously reported in other 
systems (Hwang et aLl., 1988; Ponpipom et al.,  1988). The 
IC~o for each compound varied from experiment to experi- 
ment, which may have been due to variable states of the nell- 
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Figure 5. L652,731, a competitive PAF receptor antagonist, inhibits 
PMN binding to EC activated by thrombin. ECs were preincnhated 
with control buffer or buffer containing thrombin in the indicated 
concentrations for 5 min at 37°C, the solutions were removed, con- 
trol PMNs or PMNs treated with L652,731 (100 #M) were added, 
and their adherence was determined after a 5-rnin incubation (lejt). 
In parallel incubations, the same concentration of L652,731 in- 
hibited PMN binding to ECs induced by the addition of exogenous 
PAF (right),  but had a trivial effect (0-12% inhibition) on PMN 
binding induced by the addition of 10 or 100 ng/ml PMA  (not 
shown). 
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trophil PAF receptor(s) (Hwang, 1988). We then showed that 
the inhibitors blocked PMN adhesion to ECs in response to 
exogenous PAF in solution (Fig. 4), with a similar concentra- 
tion dependence and specificity to that for adhesion to gela- 
tin. L652,731 did not inhibit PAF synthesis by ECs. 
Once the conditions for competitive, specific inhibition of 
neutrophil responses to PAF were established, we asked if 
the receptor antagonists blocked PMN adhesion to thrombin- 
treated ECs. We pretreated PMNs with L652,731 and mea- 
sured their binding  to  ECs  that had  been activated with 
thrombin (Fig. 5). In three experiments in which ECs were 
activated with various concentrations of thrombin and then 
incubated with PMNs, L652,731 inhibited PMN adhesion to 
thrombin-stimulated ECs by 40-100 %. The magnitude of in- 
hibition was dependent on the concentration of thrombin; 
that is, it was less when higher concentrations of thrombin 
were used (mean inhibition 57 +  28% at 2 U/ml thrombin), 
consistent with its action as a  competitive inhibitor of the 
PAF receptor and higher concentrations of EC-associated 
PAF at higher concentrations of thrombin (Prescott et al., 
1984).  Since the affinity of L652,731 for the PAF receptor 
is two to three orders of magnitude lower than PAF (Hwang, 
1988; Ponpipom et al., 1988), the ratio of inhibitor to ligand 
may have been unfavorable for complete inhibition of PMN 
binding to ECs stimulated with maximal concentrations of 
thrombin.  A  second possibility  is  that another molecular 
species  participates  in  signaling  neutrophils  to  bind  to 
thrombin-activated ECs (Zimmerman et al., 1985; Zimmer- 
man  and  Mclntyre,  1988).  However,  in  the  experiment 
shown in Fig. 5, L652,731 caused essentially complete inhi- 
bition of adhesion at all concentrations of thrombin tested, 
demonstrating that PAF can be the sole mediator. In three ex- 
periments kadsurenone, L652,731, and a third competitive 
receptor antagonist, L659,989 (Ponpipom et al., 1988), were 
compared. Their relative binding affinities to PAF receptors 
is L659,989 > L652,731 >/kadsurenone (Hwang, 1988; Pon- 
pipom et al.,  1988), and we found that their relative poten- 
cies as inhibitors of PMN adhesion to thrombin-stimulated 
ECs had the same rank order. 
In addition to thrombin, we previously showed that LTC4 
and  H202  induce rapid  PAF  synthesis and  EC-dependent 
PMN adhesion  (Mcintyre et al.,  1986;  Zimmerman and 
Mclntyre, 1988; Lewis et al., 1988). Since our results with 
thrombin supported a direct role for PAF in signaling PMNs 
to adhere, we asked whether this was a common mechanism 
for other rapidly acting agonists. In two of  three experiments 
L652,731  inhibited PMN  adhesion to ECs  activated with 
LTC, (1 #M for 30 min) by 46 and 65 %. In three additional 
experiments, L652,731 inhibited PMN adhesion to ECs acti- 
vated with H202 (2.5-10 #M for 20 min) by 80-95%, and 
in a fourth experiment kadsurenone inhibited PMN binding 
to H202-activated ECs by 25-60%, depending on the con- 
centration of H202.  Thus,  competitive antagonists  of the 
PAF receptor inhibit PMN binding to ECs activated by three 
agonists  (thrombin,  LTC4,  H202)  that  each  induce  rapid 
EC-dependent neutrophil adhesion that temporally parallels 
the accumulation of PAE These data indicate that PAF that 
is synthesized by activated ECs mediates PMN binding, and 
are consistent with our previous observations that desensiti- 
zation of PMNs to PAF reduced their binding to ECs acti- 
vated with these agonists (Zimmerman et al.,  1985; McIn- 
tyre et al.,  1986; Lewis et al.,  1988). 
In contrast to the result with ECs stimulated by rapidly act- 
ing agonists, 1.652,731 did not inhibit PMN adhesion to ECs 
activated with TNFot (adhesion of control PMNs  to ECs 
treated with 10 U/ml TNFot for 4 h, 65  +  11%; adhesion 
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Figure 6. L652,731 does not inhibit PMN binding to EC activated 
with TNFot. Control buffer or TNFc~ was added to EC monolayers 
in complete culture medium. After a 4-h incubation, the medium 
was removed, the monolayers were washed once with HBSS, rain- 
labeled PMNs that were pretreated with I.,652,731 (100 #M) or con- 
trol solution were added, and binding was determined after a 5-min 
incubation. The dashed line indicates the binding of PMNs to EC 
treated with control buffer. In parallel incubations, I..652,731 com- 
pletely inhibited PMN binding induced by the addition of exoge- 
nous PAF (10  -8 or 10  -7 M) (not shown). 
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Figure Z PAF in liposomes induces PMN binding to EC monolay- 
ers.  PAF in various concentrations  was sonicated with phospha- 
tidylcholine  to  form PAF-loaded liposomes  (see  Materials  and 
Methods), or was diluted in HBSSIA. PAF in HBSSIA or liposomal 
PAF was added to rain-labeled  PMNs overlying EC monolayers 
and adhesion of PMNs to the ECs was determined after a 5-rain 
incubation. The binding of PMNs in response to control buffer or 
control liposomes was 4%  in each case. In parallel  incubations, 
control PMNs or PMNs treated with L652,731 (100 #M) were in- 
cubated with 10  -g M PAF or liposomal PAE and their adhesion to 
gelatin matrices was measured after a 5-min incubation. The results 
were 33% for PAF  +  control  PMNs;  4% for PAF  +  L652,731- 
treated PMNs; 28% for liposomal PAF +  control PMNs, and 2% 
for liposomal PAF  +  L652,731-treated PMNs. 
of L652,731-treated PMNs, 65  +  8%; n  =  4), regardless of 
the concentration of the cytokine (Fig.  6).  These observa- 
tions demonstrate that the PAF receptor antagonist does not 
have toxic or nonspecific effects on EC-dependent neutrophil 
adhesion, and indicate that, although treatment of ECs with 
TNFo~ has been reported to induce the synthesis of PAF (Bus- 
solino et al.,  1988), the major mechanism of PMN binding 
to cytokine-activated ECs involves molecules other than PAF 
(Bevilacqua et al., 1987, 1989; Smith et al., 1988). Recently, 
Brevario et al. (1988) concluded that PAF synthesized by IL- 
I-activated ECs does not contribute significantly to PMN 
adhesion to them. 
PAF in Liposomes and Associated with the EC Surface 
Induces Neutrophil Binding 
An unexplained feature of these results is how a small mole- 
cule such as PAF can remain associated with the surface of 
one cell and still interact with its receptor on the target cell. 
We examined this issue with two experimental strategies. In 
the first, we incorporated PAF into liposomes, added these, 
or control liposomes, to PMN suspensions,  and measured 
adhesive responses of the neutrophils. In parallel incubations 
we  found  that  [3H-acetyl]PAF  remained  associated  with 
liposomes under the conditions of these experiments and was 
not released into buffer alone, or buffer containing 0.5 mg/ml 
human albumin. PAF-loaded liposomes induced adherence 
of PMNs to protein matrices with the same potency as mono- 
meric PAF,  while control liposomes caused adhesion that 
was similar to buffer alone (buffer, 9  +  0% adherence; con- 
trol liposomes,  11.5 +  3.5%;  monomeric PAF at  10  -6 M, 
71  +  8%; liposomes loaded with 10-* M  PAF, 72  +  8%; n 
=  2). The enhanced adhesion induced by liposomal PAF was 
completely blocked by pretreatment of the PMNs with the 
receptor antagonist L652,731  (Fig.  7).  Furthermore,  lipo- 
somal PAF also induced the rapid adhesion of PMNs to ECs 
(Fig. 7). Thus, PAF presented in model membranes can in- 
duce PMN binding to surfaces by interacting with receptors 
on the neutrophils, suggesting that PAF associated with EC 
plasma membranes may do the same. We also found that 
PAF-loaded liposomes stimulate the aggregation of human 
platelets  (unpublished  observation)  and  it  has  previously 
been reported that liposomal PAF can activate macrophages 
(Hayashi et al., 1985), although in the latter experiments the 
response required hours and may have involved internaliza- 
tion of the lipid vesicles. 
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Figure 8. Exogenous PAF associated with EC plasma membranes 
induces  PMN  binding.  EC  monolayets  were  pretreated  with 
HBSS/A or I-IBSS/A  containing various concentrations of PAF for 
5 min at 37°C; the solutions were removed, the monolayers were 
washed once with HBSS/A, and then were incubated with control 
buffer (e) or purified AH (o) for 15 min at 37°C. The buffer or AH 
was removed,  rain-labeled  PMNs were added,  and their binding 
was determined after a 5-min incubation. The figure indicates the 
mean of duplicate determinations  at each point.  The adhesion of 
rain-labeled  PMNs  to EC  treated  with control  buffer (no PAF) 
was 5%. 
In several additional experiments in which PAF was "presented" 
to PMNs associated with the EC surface (as in this figure) or in the 
fluid phase (as in Fig. 4), we saw a descending limb in the concen- 
tration-response  relationship,  similar to that shown here, at con- 
centrations of PAF greater than 10  -7 M. A biphasic pattern includ- 
ing decreased response at increasing concentrations of agunist has 
been  reported  for several PMN activities  and  with a variety of 
agonists, including PAF (Fernandez et al.,  1978; Donabedian and 
Gallin,  1981; O'Flaherty  et al.,  1981; Shaw et al.,  1981). 
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PAF added exogenously to the EC surface could directly in- 
duce PMN binding. We treated EC monolayers with PAF or 
buffer for various times,  washed  the  ECs  with albumin- 
containing buffer, and then measured the adhesion of PMNs. 
Pretreatment of ECs with PAF (5 min) resulted in enhanced 
adhesion (buffer-pretreated ECs, 7.5  -t-  3%;  10  -7 M  PAF, 
24 +  11%, n =  4) (Fig. 8). In contrast, pretreatment of ECs 
under identical conditions with the biologically inactive com- 
pound, lyso-PAE did not induce neutrophil binding. Pretreat- 
ment of ECs with PAF (10  -7 or 10  -~ M) did not induce en- 
hanced binding of HL60 cells (Table I). 
We  incubated ECs with PAF radiolabeled in  the alkyl 
chain at sn-I ([3H-alkyl]PAF)  and demonstrated a low affin- 
ity binding site for PAE This binding was not blocked by a 
1,000-fold excess of the receptor antagonist L652,731,  indi- 
cating that it was not a typical receptor for PAF. The nature 
of the association of exogenous PAF with the EC plasma 
membrane is unknown, but it may insert into the phospho- 
lipid bilayer as it does in model membranes (Lumb et al., 
1983).  There  was  no degradation of the  exogenous  pH- 
alkyl]PAF that had bound to ECs during a 30-min incubation 
(two experiments), indicating that the exogenous PAF was 
not internalized. Furthermore, incubation of ECs that had 
exogenous [3H-alkyl]PAF  bound to their surface with the 
plasma PAF aeetylhydrolase  for 5-30 min resulted in hydrol- 
ysis of the labeled phospholipid (80-89 %, depending on the 
time of incubation and the concentration of pH-alkyl]PAF), 
with  an  accompanying  increase  in  pH-alkyl]  lyso-PAE 
These experiments demonstrated that PAF remained at the 
EC surface under conditions that resulted in PMN binding 
(Fig. 8). 
The increased binding of PMNs induced by treatment of 
EC with PAF could have been due to interaction of PAF 
localized on the EC surface with the neutrophils, or to activa- 
tion of the ECs by PAF (Bussolino et al., 1987b;  Hirafuji et 
al., 1988), causing them to express a second adhesive mole- 
cule. To differentiate  between these two possibilities, we pre- 
ti'eated ECs with PAF and then incubated the monolayers 
with AH, or with control buffer, before adding PMNs and 
measuring their adhesion (Fig. 8). Incubation of EC mono- 
layers with AH completely prevented PMN binding to ECs 
that had been pretreated with 10  -s M  or 10  -7 M  PAF, but 
did not significantly alter binding to ECs pretreated with 
10  -6 M  PAE  The latter result is explained by our finding 
that, when 10  -6 M PAF was used to pretreat the ECs, only 
89 % of it was hydmlyzed in the subsequent incubation with 
AH, based on degradation of [3H-alkyl]PAF  measured in 
parallel. Thus, the residual PAF (=10  -7 M) was sufficient to 
account for the PMN binding. To further exclude the possi- 
bility that PAF induced a functional alteration in the ECs by 
interacting with cell surface receptors, we incubated ECs with 
PAF (10  -7 M)  in the presence or absence of a  1,000-fold 
higher concentration of L652,731.  Inclusion of the receptor 
antagonist in the incubation, followed by washing and addi- 
tion of "~In-labeled PMNs, had no effect on the enhanced 
PMN adhesion to PAF-treated monolayers. In contrast, in- 
clusion of L652,731  in the buffer with "'In-labeled PMNs 
completely blocked their binding to EC pretreated with PAF 
(10-8-10 -~ M), demonstrating that the mechanism of bind- 
ing involved ligation of the neutrophil PAF receptor by PAF 
on the EC surface. These experiments demonstrate that PAF 
on the surface of ECs can induce PMN  adhesion via its 
receptor on neutrophils. 
Discussion 
The experiments in this report demonstrate a novel mecha- 
nism for cell-cell interaction: a phospholipid, PAF, synthe- 
sized by ECs in response to an agonist, is rapidly and tran- 
siently expressed on the cell surface and signals neutrophils 
to bind. Although it has been observed recently that glyco- 
lipids, like glycoproteins, can mediate cell-cell and cell-ma- 
trix interaction (Cheresh et al., 1986; Sariola et al., 1988), 
and that membrane phospholipid content and distribution may 
influence erythrocyte intercellular interactions (Franck et 
al.,  1985;  Schwartz et al.,  1985;  Mikkelsen et al.,  1988), 
neutrophil binding in response to EC-associated PAF repre- 
sents the first instance in which a phospholipid that is synthe- 
sized in a regulated fashion and that is retained by its parent 
cell induces intercellular adhesion. These results support pre- 
vious observations that suggested this hypothesis (Zimmer- 
man et al.,  1985;  Mclntyre et al.,  1986;  Zimmerman and 
Mclntyre, 1988; Lewis et al., 1988): (a) agonists that induce 
rapid PAF synthesis by ECs (thrombin, LTC4,  H202),  also 
induce rapid EC-dependent PMN adhesion; (b) the concen- 
tration-response relationships and specificities of this spec- 
trum of agonists are the same for the two responses; (c) there 
is tight temporal coupling between the accumulation and 
degradation of PAF and the development and reversal of EC- 
dependent adhesion; and, (d) "desensitization" of the PAF 
receptor on PMNs specifically inhibits their binding to ECs 
activated with these agonists. In addition to these charac- 
teristics, preliminary experiments indicate that PAF synthe- 
sis and rapid EC-dependent PMN adhesion share similar 
signal transduction mechanisms: they have the same require- 
ment for extraceUular Ca  ++ and, in the case of receptor-me- 
diated agonists, may share a common guanyl nucleotide-bind- 
ing regulatory protein (our unpublished results). 
Two pathways for PAF synthesis have been identified in 
mammalian cells (Snyder, 1987). Human ECs do not appear 
to use the DTT-insensitive  cholinephosphotransferase path- 
way (Blank et al., 1986; Bussolino, 1987a), but instead syn- 
thesize PAF in a two-step reaction in which a phospholipid 
precursor,  1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine,  is 
hydrolyzed by a  phospholipase  A2  yielding  1-O-alkyl-sn- 
glycero-3-phosphocholine, which is then acetylated at the 
sn-2 position by an acetyltransferase to yield PAF (Prescott 
et al., 1984; Whatley et al., 1989). Although we cannot ex- 
clude the possibility that PAF is synthesized in the plasma 
membrane, we assume that the major site of PAF synthesis 
in ECs is the endoplasmic reticulum based on the location 
of phospholipid synthesis in mammalian cells (Bishop and 
Bell, 1988), and the localization of PAF acetyltransferase in 
microsomes from several cells and tissues (Ribbes et al., 
1985;  Snyder,  1987;  Mollinedo et al.,  1988).  In  human 
PMNs, both PLA2 and acetyltransferase activities are found 
in intracellular organdies; the acetyltransferase is localized 
in  microsomal and granular fractions  (Mollinedo et al., 
1988).  Observations in our laboratory indicate that there is 
a  similar localization of acetyltransferase activity in intra- 
cellular organelles of human ECs (our unpublished results). 
The mechanism of its intracellular transport and the specific 
orientation of the fraction found in the plasma membrane of 
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Figure  9.  Potential mechanisms for PAF localization in the EC 
plasma membrane. PAF is synthesized  in an intracellular membra- 
nous organelle, presumably the ER. A portion of  the newly synthe- 
sized PAF is then rapidly transported to the inner leaflet of the 
plasma membrane by a phospholipid  transport protein (Bishop and 
Bell, 1988), shown in A; putative PAF transport proteins have been 
identified in other cell types (Banks et al.,  1988). A "flippase" 
(Bishop and Bell, 1988) catalyzes  the rapid transmembrane  transfer 
of PAF to the outer leaflet of the plasma membrane where PAF is 
localized in the phospholipid milieu (position 1) or by noncovalent 
binding to one or more surface proteins (position 2). The flippase 
may also transfer the PAF back to the inner leaflet, where it is acces- 
sible to degradation by the intracellular PAF All. Alternatively, 
PAF may be translocated from the site of synthesis to the outer 
leaflet of the plasma membrane by vesicular flow and fusion (B); 
association with a "presenting  protein" may occur in the intracellu- 
lar organelle(s) rather than at the EC surface. 
ECs remain to be defined. Several possibilities are shown in 
the model illustrated in Fig. 9. PAF may reach the surface 
by a lipid transport protein (A in Fig. 9) or by vesicular fusion 
(B in Fig. 9) (Bishop and Bell, 1988).  In the plasma mem- 
brane, PAF may be in the outer leaflet of the bilayer (location 
1 in Fig. 9). Our experiments with PAF-loaded liposomes in- 
dicate that PAF in a lipid membrane can interact with its re- 
ceptors on neutrophils. A second possibility is that PAF is 
noncovalently linked to one or more surface proteins of ECs 
(location 2 in Fig. 9). This mechanism of presentation is an 
attractive possibility since it would place PAF  in a  more 
prominent and accessible location than if it were inserted in 
the phospholipid bilayer.  However,  our experiments  with 
proteases did not support such a model, unless the putative 
binding protein is resistant to cleavage.  Also, if our experi- 
ments with liposomes reflect what occurs at the surface of 
a biologic membrane, a "presenting protein" is not required. 
How PAF in a bilayer interacts with a receptor on another 
cell is not clear. One potential mechanism, which is not shown 
in the figure, is that PAF transfers from the EC membrane 
to its receptor on the PMN when the two cells are in close 
proximity. Against this possibility is our previous observa- 
tion that endogenously synthesized PAF is not extracted from 
the ECs by high concentrations of albumin (Mclntyre et al., 
1985),  which binds PAF. However,  it is possible that the 
affinity of the neutrophil receptor for PAF is higher enough 
than that of albumin to alter the partitioning of the phospho- 
lipid. It is also possible that PAF can remain in the bilayer 
and cause localized changes that allow it to be recognized by 
the receptor. For example, PAF causes disordering in model 
membranes (Bratton et al.,  1988) and, particularly if it is 
clustered in domains in the EC plasma membrane (location 
1 in Fig. 9), might cause such an effect (Karnovsky et al., 
1982;  Spector and Yorek,  1985). 
The EC-dependent binding of PMNs induced by PAF ap- 
pears to require a response from the PMN that then results 
in the adhesive interaction. This is suggested by preliminary 
experiments in which we found that PMN binding to throm- 
bin-activated ECs was inhibited by fixation of the neutrophils 
or by cooling them to 4°C (our unpublished observation). 
One such mechanism could be upregulation of CDtt/CDIg 
glycoproteins in the PMN plasma membrane in response to 
EC-associated PAE However, monoclonal antibodies against 
CD,/CD~8 only partially inhibited PMN adhesion to throm- 
bin-stimulated ECs (Zimmerman and Mclntyre, 1988). This 
result has several potential interpretations, including the pos- 
sibilities that CD, dCD,s glycoproteins are expressed in lo- 
calized domains (Pop et al.,  1988; Wright et al., 1988) that 
were not accessible to the antibodies, that the affinity  of  bind- 
ing of CD./CD~8 heterodimers to their "ligands  ~ on activated 
ECs is different from the affinity of binding to ligands on 
resting ECs, or that additional proadhesive molecules are ex- 
pressed by thrombin-activated ECs. PMN binding to rapidly 
activated ECs may be similar to lymphocyte  adhesion to vas- 
cular endothelium, which potentially involves at least three 
distinct molecular interactions (Dustin and Springer, 1988). 
PAF synthesis occurs in ECs that are stimulated in situ 
(Whatley et al., 1988), as well as in cultured ECs, and when 
human ECs are stimulated with thrombin in serum rather 
than  buffer  (our  unpublished  observation).  Furthermore, 
other agonists that induce its rapid synthesis in endothelium 
(histamine,  leukotrienes (24  and  I)4, H202)  are  important 
inflammatory mediators. Thus, rapidly induced PAF synthe- 
sis by ECs may be a mechanism that influences cell-cell in- 
teraction in  physiologic or pathologic inflammation. The 
mechanism has characteristics that may be particularly ad- 
vantageous  for  regulating  the  binding  of  PMNs  to  en- 
dothelium in vivo.  The accumulation of PAF is  maximal 
within minutes (Prescott et al., 1984; McIntyre et al., 1986; 
Lewis et al.,  1988),  a response time that is consistent with 
the rapid targeting of PMNs to localized areas that has been 
observed under some conditions in vivo (Van Furth et al., 
1979;  Harlan, 1985).  Also, the PAF that is synthesized by 
activated EC is degraded at a variable rate (Prescott et al., 
1984; Mclntyre et al., 1985; McIntyre et al., 1986), provid- 
ing a means to modulate the duration of the signal. Consis- 
tent  with this,  EC-dependent PMN  adhesion induced by 
thrombin and other rapidly acting agonists is reversible with 
an "off-rate" that parallels the degradation of newly synthe- 
sized PAF (Fig. 1) (Zimmerman et al., 1985, 1986; McIntyre 
et al.,  1986).  A crucial point is that PAF is retained, rather 
than being released, by ECs (McIntyre et al., 1985; Whatley 
et al., 1988). This has the potential to localize the signal, and 
thereby prevent indiscriminant activation of PMNs in the 
fluid phase. Thus, synthesis of PAF by ECs provides a mech- 
anism for rapid induction of EC-dependent PMN adhesion 
of variable,  transient  duration  whereas  the  synthesis  of 
ELAM-1 is a slower, more sustained mechanism for such ad- 
"the Journal of Cell Biology, Volume 110, 1990  538 herence (Fig.  1).  Since the time course of rapidly induced 
PAF accumulation overlaps that of ELAM-1  under some 
conditions (McIntyre et al., 1986), the two mechanisms have 
the potential to act in concert to cause both immediate and 
prolonged EC-dependent recruitment of neutrophils at sites 
of inflammation. 
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